Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

(MedPage Today) -- At the American Society of Clinical Oncology (ASCO) annual meeting, positive findings were presented on two phase III trials--DREAMM-7 and DREAMM-8--testing belantamab mafodotin (Blenrep) in multiple myeloma. Belantamab...